BioLife Solutions, Inc. FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026
BioLife Solutions, Inc. (BLFS) reported its quarterly financial results for the period ended June 30, 2026. The company’s revenue increased by 25% to $23.1 million, driven by growth in its Cryoport and BioLife Logistics segments. Net income was $2.1 million, or $0.04 per diluted share, compared to a net loss of $1.4 million, or $0.03 per diluted share, in the same period last year. The company’s cash and cash equivalents increased to $34.4 million, and its total debt decreased to $12.5 million. BioLife Solutions also reported a significant increase in its backlog, with a total of $143.1 million in orders received during the quarter. The company’s management attributed the strong results to its strategic growth initiatives, including the expansion of its logistics and storage capabilities, and the increasing demand for its cryogenic storage and transportation services.
Overview of the Company’s Financial Performance
Savsu Technologies, Inc. (the “Company” or “Savsu”) reported strong financial results for the three and six months ended June 30, 2026. The key highlights are:
Total revenue for the three months ended June 30, 2026 was $28.5 million, representing an increase of 21% compared to the same period in 2025. For the six months ended June 30, 2026, total revenue was $56.0 million, an increase of 23% compared to the same period in 2025.
The increase in revenues was largely driven by an increase in customer demand for the company’s biopreservation media products.
Gross profit for the three months ended June 30, 2026 was $18.3 million, an increase of 20% compared to the same period in 2025. Gross profit for the six months ended June 30, 2026 was $35.8 million, an increase of 19% compared to the same period in 2025.
Gross margin decreased by 1% for the three months ended June 30, 2026 and 2% for the six months ended June 30, 2026 compared to the same periods in the prior year, primarily due to a less favorable product mix.
Operating expenses decreased by 47% for the three months ended June 30, 2026 and 27% for the six months ended June 30, 2026 compared to the same periods in the prior year, primarily due to the absence of a $15.5 million IPR&D expense recorded in 2025 related to the PanTHERA acquisition.
The company had $113.1 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2026.
Revenue and Profit Trends
Savsu’s revenue growth was driven by increased customer demand for its biopreservation media products. The company saw a 21% increase in revenue for the three months ended June 30, 2026 and a 23% increase for the six months ended June 30, 2026 compared to the same periods in the prior year.
While gross profit increased by 20% and 19% for the three and six month periods, respectively, gross margin declined slightly due to a less favorable product mix. The company’s operating expenses decreased significantly, primarily due to the absence of a large IPR&D expense recorded in 2025 related to the PanTHERA acquisition.
Strengths and Weaknesses
Strengths:
- Strong revenue growth driven by increased demand for biopreservation media products
- Solid gross profit and margins, despite some decline
- Significant reduction in operating expenses compared to the prior year
Weaknesses:
- Slight decline in gross margins due to less favorable product mix
- Reliance on a few key product lines for revenue growth
Outlook
Savsu appears to be in a strong financial position, with ample cash and cash equivalents to fund its operations and potential future investments. The company’s core biopreservation media business continues to perform well, driving solid revenue and profit growth. However, the company will need to monitor its product mix and costs to maintain healthy margins going forward. Overall, the outlook for Savsu seems positive, though the company may face some challenges in sustaining its rapid growth pace.
